Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients

[11] Colevas AD(2000)New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205-216

[12] Setser A(2011)One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients Eur J Cancer 47 1521-1526

[13] Marrero JA(2011)Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma Crit Rev Oncol Hematol 77 221-240

[14] Kudo M(2017)Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study J Clin Oncol 35 3575-3581

[15] Venook AP(2017)Sorafenib dose escalation in treatment-naive patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study BJU Int 119 846-853

[16] Vincenzi B(2019)Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: a pooled analysis of clinical trial data Pigment Cell Melanoma Res 32 576-583

[17] Santini D(2019)Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients Breast Cancer Res Treat 178 473-477

[18] Russo A(2019)Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: results from a global real-world study (RealGiDo) Lung Cancer 127 103-111

[19] Llovet JM(2012)Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo Mol Cancer Ther 11 2284-2293

[20] Ricci S(2017)Hand-foot syndrome and post-progression treatment are the good predictors of better survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study Oncology 93 113-119

[11] Colevas AD(2000)New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205-216

[12] Setser A(2011)One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients Eur J Cancer 47 1521-1526

[13] Marrero JA(2011)Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma Crit Rev Oncol Hematol 77 221-240

[14] Kudo M(2017)Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study J Clin Oncol 35 3575-3581

[15] Venook AP(2017)Sorafenib dose escalation in treatment-naive patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study BJU Int 119 846-853

[16] Vincenzi B(2019)Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: a pooled analysis of clinical trial data Pigment Cell Melanoma Res 32 576-583

[17] Santini D(2019)Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients Breast Cancer Res Treat 178 473-477

[18] Russo A(2019)Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: results from a global real-world study (RealGiDo) Lung Cancer 127 103-111

[19] Llovet JM(2012)Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo Mol Cancer Ther 11 2284-2293

[20] Ricci S(2017)Hand-foot syndrome and post-progression treatment are the good predictors of better survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study Oncology 93 113-119